A randomized, open-label, multi-center, active-controlled phase II study comparing abiraterone acetate tablets (II), an improved formulation, versus originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer

A randomized, open-label, multi-center, active-controlled phase II study comparing abiraterone acetate tablets (II), an improved formulation, versus originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer

Abstract Background Abiraterone is a 17α-hydroxylase/C17-20 lyase inhibitor used for the treatment of metastatic castration-resistant prostate cancer (CRPC). This multi-center, randomized, open-label, active-controlled phase II study compared the pharmacodynamics (PD), pharmacokinetics (PK), and saf...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaolin Lu, Tao Dai, Xue Chen, Bin Wu, Hui Chen, Jitao Wu, Dexin Yu, Huixin Ge, Jian Li, Houbao Huang, Tiwu Fan, Linzhong Cheng, Xiaoping Zhang, Xuepei Zhang, Xin Yao, Junli Wei, Zhenqiang Xu, Wenzeng Yang, Chaohong He, Jiexin Luo, Ling Guan, Bin Fu, Qilin Wang, Xiaofeng Chen, Yongdong Zhang, Benkang Shi, Bin Zheng, Yong Wang, Hong Luo, Guoqiang Chen, Huan Wang, Quanren Wang, Dingwei Ye
Format: Article
Language:English
Published: BMC 2025-05-01
Series:BMC Medicine
Subjects:
Castration-resistant prostate cancer
Abiraterone acetate
CYP17 inhibitor
Testosterone
Prostate-specific antigen
Online Access:https://doi.org/10.1186/s12916-025-04053-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12916-025-04053-7

Similar Items